Page 142 - MI-2-2

Microbes & Immunity Establishment of a novel anti-human CCR8 monoclonal antibody

14. Sakaguchi S. Regulatory T cells: Key controllers of 25. Plitas G, Konopacki C, Wu K, et al. Regulatory T cells
immunologic self-tolerance. Cell. 2000;101(5):455-458. exhibit distinct features in human breast cancer. Immunity.
2016;45(5):1122-1134.
doi: 10.1016/s0092-8674(00)80856-9
doi: 10.1016/j.immuni.2016.10.032
15. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of
a new forkhead/winged-helix protein, scurfin, results in the 26. Barsheshet Y, Wildbaum G, Levy E, et al. CCR8(+)FOXp3(+)
fatal lymphoproliferative disorder of the scurfy mouse. Nat Treg cells as master drivers of immune regulation. Proc Natl
Genet. 2001;27(1):68-73. Acad Sci U S A. 2017;114(23):6086-6091.
doi: 10.1038/83784 doi: 10.1073/pnas.1621280114
16. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self- 27. Nagira Y, Nagira M, Nagai R, et al. S-531011, a novel anti-
tolerance maintained by CD25+CD4+ naturally anergic human CCR8 antibody, induces potent antitumor responses
and suppressive T cells: Induction of autoimmune disease through depletion of tumor-infiltrating CCR8-expressing
by breaking their anergic/suppressive state. Int Immunol. regulatory T cells. Mol Cancer Ther. 2023;22(9):1063-1072.
1998;10(12):1969-1980. doi: 10.1158/1535-7163.Mct-22-0570
doi: 10.1093/intimm/10.12.1969 28. Wu Y, Xi J, Li Y, et al. Discovery of a potent and selective
17. Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory CCR8 small molecular antagonist IPG7236 for the treatment
T cells as targets of cancer immunotherapy. Cancer Cell. of cancer. J Med Chem. 2023;66(7):4548-4564.
2023;41(3):450-465. doi: 10.1021/acs.jmedchem.3c00030
doi: 10.1016/j.ccell.2023.02.014 29. Kim N, Kim MH, Pyo J, et al. CCR8 as a therapeutic
18. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the novel target: Omics-integrated comprehensive analysis
development and function of CD4+CD25+ regulatory T for systematically prioritizing indications. Biomedicines.
cells. Nat Immunol. 2003;4(4):330-336. 2023;11(11):2910.

doi: 10.1038/ni904 doi: 10.3390/biomedicines11112910
19. Mortezaee K. Selective targeting or reprogramming of intra- 30. Märkl F, Huynh D, Endres S, Kobold S. Utilizing chemokines
tumoral Tregs. Med Oncol. 2024;41(3):71. in cancer immunotherapy. Trends Cancer. 2022;8(8):
670-682.
doi: 10.1007/s12032-024-02300-0
doi: 10.1016/j.trecan.2022.04.001
20. Wakiyama H, Kato T, Furusawa A, et al. Treg-dominant
tumor microenvironment is responsible for hyperprogressive 31. Bernardini G, Spinetti G, Ribatti D, et al. I-309 binds to and
disease after PD-1 blockade therapy. Cancer Immunol Res. activates endothelial cell functions and acts as an angiogenic
2022;10(11):1386-1397. molecule in vivo. Blood. 2000;96(13):4039-4045.
doi: 10.1158/2326-6066.Cir-22-0041 32. Goya I, Gutiérrez J, Varona R, et al. Identification of CCR8 as
the specific receptor for the human beta-chemokine I-309:
21. Guan X, Hu R, Choi Y, et al. Anti-TIGIT antibody improves Cloning and molecular characterization of murine CCR8 as
PD-L1 blockade through myeloid and T(reg) cells. Nature. the receptor for TCA-3. J Immunol. 1998;160(4):1975-1981.
2024;627:646-655.
33. Liu X, Xu X, Deng W, et al. CCL18 enhances migration,
doi: 10.1038/s41586-024-07121-9 invasion and EMT by binding CCR8 in bladder cancer cells.
22. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Mol Med Rep. 2019;19(3):1678-1686.
adaptive, and acquired resistance to cancer immunotherapy. doi: 10.3892/mmr.2018.9791
Cell. 2017;168(4):707-723.
34. Spinetti G, Bernardini G, Camarda G, et al. The chemokine
doi: 10.1016/j.cell.2017.01.017 receptor CCR8 mediates rescue from dexamethasone-
23. Wang L, Simons DL, Lu X, et al. Connecting blood and induced apoptosis via an ERK-dependent pathway. J Leukoc
intratumoral Treg cell activity in predicting future relapse in Biol. 2003;73(1):201-207.
breast cancer. Nat Immunol. 2019;20(9):1220-1230. doi: 10.1189/jlb.0302105
doi: 10.1038/s41590-019-0429-7 35. Denis C, Deiteren K, Mortier A, et al. C-terminal clipping
of chemokine CCL1/I-309 enhances CCR8-mediated
24. De Simone M, Arrigoni A, Rossetti G, et al. Transcriptional
landscape of human tissue lymphocytes unveils uniqueness intracellular calcium release and anti-apoptotic activity.
of tumor-infiltrating T regulatory cells. Immunity. PLoS One. 2012;7(3):e34199.
2016;45(5):1135-1147. doi: 10.1371/journal.pone.0034199
doi: 10.1016/j.immuni.2016.10.021 36. Campbell JR, McDonald BR, Mesko PB, et al. Fc-optimized

Volume 2 Issue 2 (2025) 134 doi: 10.36922/mi.4661